Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Curis, Inc.
Inhibitors of Hedgehog signaling pathway block growth of prostate cancer cells
September 24th, 2004
Curis, Inc., (CRIS) announced that the Proceedings of the National Academy of Sciences USA contains a report demonstrating that inhibition of Hedgehog signaling pathway can block the growth of certain prostate cancer cell lines and primary tumor cultures. The authors suggest that drug candidates based on Hedgehog pathway inhibition may "provide attractive therapeutic strategies to combat prostate cancer of any grade." The scientific article is entitled "Inhibition of Prostate Cancer Proliferation by Interference with Sonic Hedgehog-Gli1 Signaling." The authors report that Hedgehog signaling levels are often abnormally elevated relative to...
Source: Food & Drug Law Weekly (2004-09-24)
|
